Mounjaro vs. Ozempic: separating TikTok hype from trial data

What did @mariih.fit actually say?

Straightforwardly: nothing medical. The transcript is song lyrics, not health advice. The words "He told me, console me, and then I leave without a trace" and "Get up" are from a pop track, not a discussion of tirzepatide, semaglutide, or any GLP-1 therapy. There are zero clinical claims to evaluate here.

The video's relevance to GLP-1 medications comes entirely from its hashtags: #mounjaro, #ozempic, and the misspelled #tizerpatida (the drug is tirzepatide). This is a common TikTok pattern where creators tag trending medical topics to reach health-curious audiences without actually saying anything that can be fact-checked or flagged. It is worth naming that tactic plainly.

Because the creator made no spoken or written claims about these drugs, there is nothing to verify, correct, or endorse from the transcript itself.

Does the science back this up?

There is no claim to test against the evidence. But since nearly a million people landed on this video through GLP-1 hashtags, the science these viewers are likely searching for is worth laying out clearly and accurately.

Tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity, is a dual GIP and GLP-1 receptor agonist. In the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), adults with obesity taking 15 mg tirzepatide lost a mean of 20.9% of body weight over 72 weeks. That is a meaningfully larger effect than semaglutide 2.4 mg showed in the STEP-1 trial (Wilding et al., 2021, NEJM), where mean weight loss was 14.9%. A head-to-head trial, SURMOUNT-5, published in 2025, confirmed tirzepatide outperformed semaglutide on weight loss endpoints. Neither drug is a cure for obesity, and discontinuation typically results in weight regain (Wilding et al., 2022, Diabetes, Obesity and Metabolism).

What did they get wrong (or right)?

The creator got nothing wrong in a factual sense because they said nothing factual. But framing a nearly million-view video around GLP-1 drug names without providing any context is its own kind of problem. Viewers searching #ozempic or #mounjaro on TikTok are often newly prescribed patients or people considering treatment. They deserve information, not a soundtrack.

What the video accidentally does right: it does not spread misinformation. No one is telling viewers that tirzepatide "melts fat," that compounded semaglutide is identical to Ozempic, or that these drugs work without lifestyle changes. Those false claims are rampant in this hashtag ecosystem. Silence, in this case, is not harmful. It is just not useful.

The misspelling "tizerpatida" in the hashtag is minor but worth noting because it suggests the creator is engaging with these drug names as trend tokens rather than as medications with real clinical profiles.

What should you actually know?

If you arrived at this video hoping to learn something about Mounjaro or Ozempic, here is what the research actually supports.

• Tirzepatide and semaglutide are not the same drug. They work on overlapping but distinct receptor pathways. Tirzepatide hits both GIP and GLP-1 receptors; semaglutide targets GLP-1 only.
• Compounded versions of these drugs are not equivalent to brand-name products. The FDA has never approved compounded semaglutide or tirzepatide as interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound. Salt-form compounding raises additional safety concerns the agency has flagged explicitly.
• Side effects are real and common. Nausea, vomiting, and gastrointestinal symptoms affect a significant portion of patients, particularly during dose escalation (Davies et al., 2021, Lancet).
• These are not quick fixes. The weight-loss benefits in clinical trials required 68 to 72 weeks of continuous treatment. Long-term data on cardiovascular outcomes for tirzepatide in obesity, beyond the SELECT trial findings for semaglutide (Lincoff et al., 2023, NEJM), is still accumulating.
• A prescriber and a real conversation about your health history are not optional steps.